"BMS" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonBMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts - BioSpace
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts BioSpace
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yaho...
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know Yahoo Finance
Lucia and Heart Rhythm Society Announce Strategic Collaboration to Enhance UpBeat.org for AFib Pa...
About us - Bristol Myers Squibb
About us Bristol Myers Squibb
Independent research - Bristol Myers Squibb
Independent research Bristol Myers Squibb
BMS in der Schweiz - Bristol Myers Squibb
BMS in der Schweiz Bristol Myers Squibb
Our science - Bristol Myers Squibb
Our science Bristol Myers Squibb
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes - FiercePharma
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes FiercePharma
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
The Bristol Myers Squibb Foundation Bristol Myers Squibb
Pharmaceutical business development - Bristol Myers Squibb
Pharmaceutical business development Bristol Myers Squibb
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales - FiercePh...
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales FiercePharma
Global Inclusion & Diversity - Bristol Myers Squibb
Global Inclusion & Diversity Bristol Myers Squibb
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees BioSpace
BMS Aluminum Replacement muyrecomendable Charge - The Branding Iron
BMS Aluminum Replacement muyrecomendable Charge The Branding Iron
BMS, Takeda's Chinese partners file for IPOs, sending Ascentage, Biokin and Bao bundling toward l...
BMS, Takeda's Chinese partners file for IPOs, sending Ascentage, Biokin and Bao bundling toward listings Fierce Biotech
Spotlight on BMS Literacy! - TAPinto.net
Spotlight on BMS Literacy! TAPinto.net
Working at BMS - Bristol Myers Squibb
Working at BMS Bristol Myers Squibb
Our impact - Bristol Myers Squibb
Our impact Bristol Myers Squibb
Our technologies - Bristol Myers Squibb
Our technologies Bristol Myers Squibb
Transparency & reporting - Bristol Myers Squibb
Transparency & reporting Bristol Myers Squibb
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference - Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference Business Wire
Our company: Industry leadership in BioPharma - Bristol Myers Squibb
Our company: Industry leadership in BioPharma Bristol Myers Squibb
Areas of interest - Bristol Myers Squibb
Areas of interest Bristol Myers Squibb
Global Inclusion & Diversity Report - Bristol Myers Squibb
Global Inclusion & Diversity Report Bristol Myers Squibb
Get help paying for your medicines - Bristol Myers Squibb
Get help paying for your medicines Bristol Myers Squibb
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version - FiercePh...
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version FiercePharma
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Inj...
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2 Bristol Myers Squibb - News
People and business resource groups - Bristol Myers Squibb
People and business resource groups Bristol Myers Squibb
Clinical trials & studies - Bristol Myers Squibb
Clinical trials & studies Bristol Myers Squibb
Become a business supplier - Bristol Myers Squibb
Become a business supplier Bristol Myers Squibb
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials - Bristol...
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials Bristol Myers Squibb
Business development leadership team - Bristol Myers Squibb
Business development leadership team Bristol Myers Squibb
Post study drug access to BMS investigational medicinal products and approved products - Bristol ...
Post study drug access to BMS investigational medicinal products and approved products Bristol Myers Squibb
Leveraging AI to enhance workplace innovation & efficiency - Bristol Myers Squibb
Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb
Pre-approval access to investigational medicines - Bristol Myers Squibb
Pre-approval access to investigational medicines Bristol Myers Squibb
Global Patient Week 2024 - Bristol Myers Squibb
Global Patient Week 2024 Bristol Myers Squibb
Worldwide locations - Bristol Myers Squibb
Worldwide locations Bristol Myers Squibb
Professional Service Automation Software for IT Professionals | Kaseya BMS - Kaseya
Professional Service Automation Software for IT Professionals | Kaseya BMS Kaseya
Immunology patient resources - Bristol Myers Squibb
Immunology patient resources Bristol Myers Squibb
How BMS employees champion STEM education & diversity - Bristol Myers Squibb
How BMS employees champion STEM education & diversity Bristol Myers Squibb
Expanding access to lung cancer screening - Bristol Myers Squibb
Expanding access to lung cancer screening Bristol Myers Squibb
Position biopharma industry key issues - Bristol Myers Squibb
Position biopharma industry key issues Bristol Myers Squibb
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior An...
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC - OncLive
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC OncLive
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal - BioSpace
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal BioSpace
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma - OncLive
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma OncLive
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: report - FiercePharma
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: report FiercePharma
Early innovation at BMS - Bristol Myers Squibb
Early innovation at BMS Bristol Myers Squibb
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug CNBC
Translational medicine - Bristol Myers Squibb
Translational medicine Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery - Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy Bristol Myers Squibb
Survivorship Today: Cancer survivor stories - Bristol Myers Squibb
Survivorship Today: Cancer survivor stories Bristol Myers Squibb
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century BioSpace
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space - BioSpace
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space BioSpace
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls o...
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls on FiercePharma
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management - Bris...
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management Bristol Myers Squibb
Our commitment towards transforming multiple myeloma treatment - Bristol Myers Squibb
Our commitment towards transforming multiple myeloma treatment Bristol Myers Squibb
Celebrating four years of patient engagement through PEER program - Bristol Myers Squibb
Celebrating four years of patient engagement through PEER program Bristol Myers Squibb
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing - Bristol...
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing Bristol Myers Squibb
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Centu...
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics Fierce Biotech
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) - Bristol Mye...
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) Bristol Myers Squibb
Bengaluru: BMS Education Trust told to vacate land belonging to temple - Deccan Herald
Bengaluru: BMS Education Trust told to vacate land belonging to temple Deccan Herald
ASPIRE: Our commitment to address health inequities in low- and middle-income countries - Bristol...
ASPIRE: Our commitment to address health inequities in low- and middle-income countries Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation - Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation Bristol Myers Squibb
Advancing one’s growth and career development through a culture of inclusion and belonging - Bris...
Advancing one’s growth and career development through a culture of inclusion and belonging Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition - Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry - Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry Bristol Myers Squibb
Chris Boerner, PhD - Bristol Myers Squibb
Chris Boerner, PhD Bristol Myers Squibb
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 - Fierce Biotech
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 Fierce Biotech
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors -...
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance
Driving innovative and inclusive practices at all levels of the BMS organization - Bristol Myers ...
Driving innovative and inclusive practices at all levels of the BMS organization Bristol Myers Squibb
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $...
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research Bristol Myers Squibb - News
Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M - Fierce ...
Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M Fierce Biotech
Unusual Liposome Image During Drug Research and Development - Bristol Myers Squibb
Unusual Liposome Image During Drug Research and Development Bristol Myers Squibb
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research - Bristol Myers Squibb
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research Bristol Myers Squibb
Advances in the Science of Immune-Mediated Diseases Treatment - Bristol Myers Squibb
Advances in the Science of Immune-Mediated Diseases Treatment Bristol Myers Squibb
90 hours work per week will ruin health of workers, says BMS Vizianagaram president - The Hindu
90 hours work per week will ruin health of workers, says BMS Vizianagaram president The Hindu
Mohit Dhingra, Vice President, Technology, and Managing Director, BMS Hyderabad - Bristol Myers S...
Mohit Dhingra, Vice President, Technology, and Managing Director, BMS Hyderabad Bristol Myers Squibb
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' - ...
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' FiercePharma
Highlights from our 2024 Climate Change Report - Bristol Myers Squibb
Highlights from our 2024 Climate Change Report Bristol Myers Squibb
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on - Fierce...
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on FiercePharma
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it? Bristol Myers Squibb
Working together to advance research in liver disease - Bristol Myers Squibb
Working together to advance research in liver disease Bristol Myers Squibb
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia - BioSpace
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia BioSpace
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb
Pioneering Innovative Drug Development at Cambridge Crossing Facility Bristol Myers Squibb
Leading innovation in cardiovascular disease - Bristol Myers Squibb
Leading innovation in cardiovascular disease Bristol Myers Squibb
Spreading eosinophilic esophagitis awareness and wellness in patients - Bristol Myers Squibb
Spreading eosinophilic esophagitis awareness and wellness in patients Bristol Myers Squibb
Driving patient-centric care through global patient outreach - Bristol Myers Squibb
Driving patient-centric care through global patient outreach Bristol Myers Squibb
Early Treatment for Rheumatoid Arthritis - Bristol Myers Squibb
Early Treatment for Rheumatoid Arthritis Bristol Myers Squibb
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Th...
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Bristol Myers Squibb - News
Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb
Bringing the science of cell therapy into autoimmune diseases Bristol Myers Squibb
2024 Annual Meeting of Shareholders - Bristol Myers Squibb
2024 Annual Meeting of Shareholders Bristol Myers Squibb
Amplifying patient voices to enhance HCM care - Bristol Myers Squibb
Amplifying patient voices to enhance HCM care Bristol Myers Squibb
Improving health literacy through Universal Patient Language program - Bristol Myers Squibb
Improving health literacy through Universal Patient Language program Bristol Myers Squibb
UTSA announces partnership with Bristol Myers Squibb to advance pharmaceutical discoveries and de...
Annual reports - Bristol Myers Squibb
Annual reports Bristol Myers Squibb
Transforming IT procurement: BMS and Lenovo make sustainability gains together - Lenovo StoryHub
Transforming IT procurement: BMS and Lenovo make sustainability gains together Lenovo StoryHub
FDA Approves First Novel Schizophrenia Drug in 35 Years - BioSpace
FDA Approves First Novel Schizophrenia Drug in 35 Years BioSpace
BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134 - BioSpace
BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134 BioSpace